Siren LLC’s Centessa Pharmaceuticals CNTA Stock Holding History

Siren LLC’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,053,464	Closed	-$41.8M	–	119
2026 Q1	$41.8M	Sell	1,053,464 -2,974,053	-74%	-$76.1M	1.16%	23
2025 Q4	$101M	Buy	4,027,517 +800,000	+25%	+$20.3M	3%	6
2025 Q3	$78.3M	Sell	3,227,517 -232,512	-7%	-$4.13M	3.06%	6
2025 Q2	$45.5M	Buy	3,460,029 +500,000	+17%	+$6.33M	2.35%	8
2025 Q1	$42.6M	Sell	2,960,029 -44,648	-1%	-$731K	2.4%	12
2024 Q4	$50.3M	Sell	3,004,677 -254,000	-8%	-$4.21M	2.22%	11
2024 Q3	$52.1M	Buy	+3,258,677	New	+$39.9M	2.6%	11

Siren LLC's CNTA Position: Q2 2026 in Review

Siren LLC sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 1,053,464 shares — an estimated $41.8M sold.

Siren LLC first reported a position in CNTA in Q3 2024 and held it in 7 quarters. The position peaked at $101M in Q4 2025. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Siren LLC reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Siren LLC sold 1,053,464 Centessa Pharmaceuticals shares in Q2 2026, an estimated $41.8M.
Siren LLC first reported a position in Centessa Pharmaceuticals in Q3 2024 and held it in 7 quarters.
Siren LLC's Centessa Pharmaceuticals position peaked at $101M in Q4 2025.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Siren LLC's 13F filing for Q2 2026, filed 13 Aug 2026.